• Customer Care
  • (888) 123-4567

POSTDOCTORAL SCIENTIST

Rise Therapeutics is recruiting a postdoctoral scientist with a background in molecular biology, immunology, and/or microbial genetic research to work in our Rockville, Maryland laboratory. This candidate should have a strong interest in developing innovative new immunological therapies. Our Postdoctoral Scientist Program offers a unique opportunity for entrepreneurial minded scientists to develop the skills and experience necessary for a successful career in the biotechnology industry. The Postdoctoral Scientist will lead research programs and product development strategies to generate pre-clinical validation datasets to support drug development programs.

Required Qualifications

  • Advanced degree (PhD and/or MD) in the life sciences
  • Background in molecular biology, immunology, and/or microbial genetic research
  • Strong verbal and written communication skills
  • Ability to contribute in a fast-paced, highly dynamic environment
  • Strong sense of responsibility for deadlines and data accuracy
  • Ability to deliver results in a highly independent environment
  • Rigor and attention to detail in all aspects of science
  • Ability to exercise discretion when handling confidential or sensitive information
  • Comfort with collaboration in a team-based environment 

Benefits

  • Develop new therapies to treat autoimmunity, infection, and cancer
  • Gain experience working in biotech
  • Mentorship from seasoned entrepreneurs and business executives
  • Ability to patent discoveries and better understand intellectual property management
  • Opportunities to publish and attend/present at scientific meetings
  • Expand relationships/connections with leading academic innovators and global biotechnology/pharmaceutical partners

 

About Rise Therapeutics

Rise Therapeutics is an emerging, privately held biotech company located in Rockville, Maryland, which develops novel synthetic biology-based medicines. As a product focused company, we leverage our proprietary drug delivery platform and GMP manufacturing infrastructure to create targeted immunologically-directed Live Biotherapeutic Products (LBPs). Rise harnesses novel discoveries in microbiome biology as it relates to regulation of immune function to identify new immune regulatory pathways and develop unique, first-in-class immune modulatory drugs for the treatment of autoimmunity, inflammation, infection, and cancer. For more information, please visit our website at www.risetherapeutics.com

 

Please email your CV or resume to: This email address is being protected from spambots. You need JavaScript enabled to view it.

Title document as "last name first inital-title of position-resume.pdf" e.g. "DoeJ-PostDoc-resume.pdf"

Our News

Biotech company receives follow-on funding to accelerate ongoing clinical development efforts

TEDCO, Maryland’s economic engine for technology companies, announced a recent Seed Funds investment of $200,000 into Rise Therapeutics, a Maryland-based biotechnology company. TEDCO’s Seed Funds invest in early-stage, technology and life sciences companies and provides access to gap financing.

 

Rockville, Maryland - Rise Therapeutics, a biotech company focused on developing novel immunological-directed synthetic biology-based therapeutics, announced today that it has received funding from the National Institutes of Health (NIH) to develop a novel therapeutic for Acute Respiratory Distress Syndrome (ARDS). The funding will support completion of product validation studies and preparation for clinical development for the program. Rise’s functionally directed immunotherapy engages natural gut microbiome-associated immunological processes with the potential to diminish lung neutrophilia, reduce inflammation, upregulate regulatory T cells, and restore airways epithelial barrier to balance and reset the patient’s immunological repertoire.

Rockville, Maryland, January 31st, 2023 – Rise Therapeutics, a biopharmaceutical company engaged in developing novel oral synthetic biology medicines, today announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application to proceed with a Phase 1 clinical trial of its lead program candidate, R-3750.